{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.7986","value":"34.40"},{"groupId":"OG001","spread":"19.455","value":"69.50"},{"groupId":"OG002","spread":"19.568","value":"88.87"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"description":"Cmax of bortezomib following intravenous administration of JNJ-26866138 at dose of 0.7, 1.0, and 1.3 mg/m2 on Cycle 2/Day 4 (combination with melphalan and prednisolone)","dispersionType":"Standard Deviation","groups":[{"description":"JNJ-26866138 0.7 mg/m2 on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 4 cycles","id":"OG000","title":"Phase I - JNJ-26866138 0.7 mg/m2 Group"},{"description":"JNJ-26866138 1.0 mg/m2 on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 4 cycles","id":"OG001","title":"Phase I - JNJ-26866138 1.0 mg/m2 Group"},{"description":"JNJ-26866138 1.3 mg/m2 on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 4 cycles","id":"OG002","title":"Phase I - JNJ-26866138 1.3 mg/m2 Group"}],"paramType":"MEAN","populationDescription":"Pharmacokinetics-evaluable population: 14 participants were included in pharmacokinetics-evaluable population during Cycle 2","reportingStatus":"POSTED","timeFrame":"Day 4 of Cycle 2","title":"Maximum Observed Plasma Concentration (Cmax) of Bortezomib (JNJ-26866138 in Combination With Melphalan and Prednisolone) - Phase I","type":"SECONDARY","unitOfMeasure":"ng/mL"}